Endocrine Abstracts

177Lu-labelled compounds show many advantages for dosimetry assessments due to the attractive physical properties of the isotope which comprise a clearly separated gamma peak at 208 keV and low abundance of photons which permits reliable quantitative imaging after therapy. In addition, the low range of beta particles is advantageous for radiation protection. This talk mainly focuses on dosimetry methodology which includes consideration of the number and time points ...

Introduction: Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin receptor (SSTR) agonists is highly effective and has become an integral part of neuroendocrine tumour (NET) treatment. However, tumour uptake and tumour-to-tissue dose ratios may be higher with radiolabelled SSTR antagonists than agonists. OPS201 (DOTA-JR11) is a very promising next-generation SSTR antagonist selective for SSTR2 (expressed by NETs). This phase 1/2, international, single-...

Objectives: Radiation induces DNA double strand breaks (DSBs) that can be visualized and enumerated as microscopic γ-H2AX and 53BP1 foci. This study analysed the dose- and time-dependency of the DNA damage in blood lymphocytes in patients after a personalised high-activity 177Lu-DOTATATE treatment.Methods: We investigated multiple blood samples of three patients up to 96 h after personalised high-activity peptide receptor radionuclid...

Introduction: Diagnostic imaging of neuroendocrine tumors (NETs) is the domain of somatostatin receptor (SSTR) agonists as well as FDG PET/CT in dedifferentiated tumors. SSTR also serves as target for receptor directed peptide therapy. More recently, specific ligands targeting the chemokine receptor 4 (CXCR4) were introduced potentially offering an additional theranostic option in NETs. Here we evaluated the CXCR4 expression using 68Ga-Pentixafor PET/CT in NET patie...